Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil

dc.creatorBuonora, Sibelle
dc.creatorNogueira, Susie
dc.creatorPone, Marcus Vinicius
dc.creatorAloé, Marisa
dc.creatorOliveira, Ricardo Hugo
dc.creatorHofer, Cristina
dc.date.accessioned2012-12-04T16:41:38Z
dc.date.accessioned2023-09-05T15:46:56Z
dc.date.available2012-12-04T16:41:38Z
dc.date.available2023-09-05T15:46:56Z
dc.date.created2012-12-04T16:41:38Z
dc.date.issued2008
dc.identifierBUONORA, Sibelle et al. Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil. Annals of Tropical Paediatrics, London, v. 28, n. 1, p. 59-64, 2008.
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/5920
dc.identifier10.1179/146532808X270699
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8670488
dc.languageeng
dc.publisherButterworths Scientific
dc.relationde Martino M, Tovo P-A, Balducci M, et al. Reduction in mortality with availability of therapy for children with perinatal HIV-1 infection. JAMA 2000; 284:190–7.
dc.relationMahoney EM, Donfield SM, Howard C, Kaufman F, Gertner JM. HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study. J Acquir Immune Defic Syndr 1999; 21:333–7.
dc.relationMatarazzo P, Palomba E, Lala R, et al. Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV-1 infection. Acta Paediatr 1994; 83:1029–34.
dc.relationBerhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics 1997; 100:e7.
dc.relationLaue L, Pizzo PA, Butler K, Cutler GB. Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr 1990; 117:541–5.
dc.relationvan Rossum AMC, Gaakeer MI, Verweel G, et al. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency vı´rus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J 2003; 22:70–6.
dc.relationArpadi SM, Cuff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversly related to viral load in HIV-infected children. J Nutr 2000; 130:2498–502.
dc.relationMcKinney RE Jr, Wilfert C. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine: AIDS Clinical Trials Group Protocol 043 Study Group. J Pediatr 1994; 125 (5 pt 1):728–33.
dc.relationNewell ML, Borja MC, Peckham C. European Collaborative Study. Height, weight and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003; 111:e52–60.
dc.relationhttp://aidsinfo.nih.gov/guidelines/pediatric/PED_032405. pdf
dc.relationCenters for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43 (RR-12):1–10.
dc.relationhttp://www.bcb.gov.br/?TXDOLAR.
dc.relationNachman SA, Lindsey JC, Moye J, et al. For the Pediatric AIDS Clinical Trials Group 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005; 24:352– 7.
dc.relationVerweel G, van Rossum AMC, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002; 109:1–7.
dc.relationMiller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 2001; 107:e77.
dc.relationDreimane D, Nielsen K, Deveiks A, Bryson YJ, Geffner ME. Effect of protease inhibitors combined with standard therapy on linear growth and weight gain in human immunodeficiency virus type 1- infected children. Pediatr Infect Dis J 2001; 20:315– 16.
dc.relationNachman SA, Lindsey JC, Pelton S, et al. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med 2002; 156:497– 503.
dc.relationGuillen S, Ramos JT, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26:334–8.
dc.relationJunqueira do Lago M, Faerstein E, de Souza Lopes C, Werneck GL. Pro-Saude Study (Rio de Janeiro, Brazil). Family socio-economic background modified secular trends in age at menarche: evidence from the Pro-Saude Study (Rio de Janeiro, Brazil). Ann Hum Biol 2003; 30:347–52.
dc.relationBuchacz K, Rogol AD, Lindsey JC, et al. Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr 2003; 33:56–65.
dc.relationde Martino M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 2001; 15:1527–34.
dc.rightsrestricted access
dc.titleGrowth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución